Abbvie Inc.

National University of Singapore

Roquette Freres

Rajeev Gokhale

Jonathan Miller

Yi Gao

Eric Allen Schmitt

Bernd Liepold

Thomas Kessler

Yi Shi

Nancy E Sever

Ping Gao

Carl M Knable

Olaf Haeusler

Mark Costello

John B Morris

Mirko Pauli

Drazen Kostelac

Peter Hoelig

Fatih Durak

Anna Moosmann

Karin Rosenblatt

Chi Zhang

Justin S Lafountaine

Susan George

Lloyd Dias

Shiqi Hong

Jian Yao Ng

Keat-Theng Chow

Yuan-Siang Lui

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

Solid antiviral dosage forms

A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer.

Solid dispersions containing kinase inhibitors

Growing community of inventors

Singapore, Singapore

Rajeev Gokhale